Actively Recruiting
Pilot Trial Evaluating Metformin Treatment for Pseudomyxoma Peritonei Caused by Appendiceal Mucinous Tumors Phase 2, Single-Group, Open-Label Study
Led by University of California, Irvine · Updated on 2026-07-13
15
Participants Needed
1
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility of metformin therapy in adults with pseudomyxoma peritonei PMP caused by appendiceal mucinous neoplasms AMNs. This pilot, open-label Phase 2 clinical trial aims to determine if patients with recurrent or refractory PMP can tolerate and adhere to metformin treatment. The study is sponsored by the University of California, Irvine. Participants will receive metformin orally at a dose of 850 mg daily. Treatment will continue for up to 18 months or until the participant cannot tolerate the medication. This is a single-group study without a placebo or comparison arm, focusing on assessing treatment feasibility. During the study, researchers will monitor participants adherence to metformin, specifically measuring the proportion who complete at least 80% of planned doses by 6 months. Additional outcomes include progression-free survival at 6, 12, and 18 months. Participants will be assessed regularly for treatment tolerance and disease progression throughout the study period.
CONDITIONS
Brief Title
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
U
University of California Irvine Medical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here